hims glp-1 california to begin selling microdosing treatments Hims & Hers to offer

Having the commercial considerations built into the research process from the beginning -- cost, supply chain, consistency -- made all the difference compared to purely academic research that might identify something impossible to commercialize

"With Foundayo, we now have an oral option that delivered an average of 12.4% weight loss at the highest dose in clinical trials addressing both the clinical realities of obesity and the practical challenges patients face every day." Supported by the ATTAIN clinical trial programme, Foundayo was proven to help people lose weight and keep it off

L., Oriana, H

Jenn and I discuss: How natural GLP-1 production can decline with age Why under-fueling is still the primary issue for many athletes Different types and forms of GLP-1 meds Who should (and shouldn't) consider these medications Potential risks of GLP-1 use, including muscle loss, bone density loss, and GI distress Potential benefits to inflammation, autoimmune conditions, gut health, and mood Nutrition and supplement strategies when appetite is lower Dosing and microdosing for therapeutic use, not just weight loss Why some athletes cycle on and off these meds, or may only need them for a short period of time Why Jenn takes most clients off GLP-1s during race training The stigma around GLP-1 use among athletes Jenn's own story: early menopause, a cardiovascular family history, and how a short course changed her running Why solid diet and lifestyle habits must always come first I hope this episode helps you better understand the complexities of GLP-1 medications in endurance athletes, and why there's rarely a simple yes-or-no answer to the questions we explore together

This meal sequencing strategy, eating protein first, has been shown to improve postprandial GLP-1 response and glucose control in multiple studies

Turck, D., et al